<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357890</url>
  </required_header>
  <id_info>
    <org_study_id>16-03890-002</org_study_id>
    <nct_id>NCT00357890</nct_id>
  </id_info>
  <brief_title>Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)</brief_title>
  <official_title>A Pilot Study of the Effect of Continuous Subcutaneous Insulin Infusion in Adolescents With Newly-diagnosed Type 1 Diabetes on Insulin Resistance, Beta-cell Function and the Honeymoon Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years
      old) will be randomized to either receive multiple daily injection (MDI) using Lantus
      insulin, or continuous subcutaneous insulin infusion (CSII; pump therapy). The proposed
      protocol compares the changes in diabetes control between pump therapy and MDI treatment
      groups. More importantly, however, the study evaluates how these modes of therapy may affect
      the honeymoon period and glycemic control, specifically focusing on changes in insulin
      sensitivity (measured by the euglycemic-hyperinsulinemic clamp studies and adiponectin
      concentration changes) and beta cell function (measured by mixed meal tolerance testing).
      Demonstrating that pump therapy at the time of diagnosis of type 1 diabetes prolongs the
      honeymoon phase by improving insulin sensitivity and beta cell function may have important
      therapeutic implications that could influence the standard of care in pediatric diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c (HbA1c or A1c)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta cell function</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Pump therapy (CSII)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of pump therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple daily injections (MDI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of MDI (basal bolus therapy with glargine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pump therapy (CSII)</intervention_name>
    <description>CSII initiated within 1 month of dx</description>
    <arm_group_label>Pump therapy (CSII)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple daily injections (MDI) using insulin glargine + rapid acting analog</intervention_name>
    <description>MDI as control</description>
    <arm_group_label>Multiple daily injections (MDI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient between the age of 12 and 17 years inclusive at time of entry
             into study (i.e., after their 12th but before their 18th birthday)

          -  Type 1 diabetes mellitus for no more than 10 days

          -  pubertal (Tanner stage 2 or above)

          -  The patient and parents or guardians should be able to do simple math calculations
             (necessary for pump management)

          -  Parent or legal guardian must give signed informed consent

        Exclusion Criteria:

          -  No other chronic medical conditions (well-controlled thyroid disease is OK, and mild
             asthma is OK if the patient is not on chronic inhaled or oral daily corticosteroids)

          -  Exceptional psychological stress, more than expected for circumstances of having the
             new diagnosis of diabetes

          -  Inability or unwillingness to comply with requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry A Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Chidlren's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2006</study_first_posted>
  <last_update_submitted>June 10, 2016</last_update_submitted>
  <last_update_submitted_qc>June 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>Larry Fox</investigator_full_name>
    <investigator_title>Pediatric Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>new onset</keyword>
  <keyword>CSII</keyword>
  <keyword>insulin glargine</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>beta cell function</keyword>
  <keyword>beta cell preservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

